Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis.

Norum, Jan; Antonsen, Margareth Aarag; Tollåli, Terje; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin Helene; Helbekkmo, Nina

Norum, Jan; Antonsen, Margareth Aarag; Tollåli, Terje; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin Helene; Helbekkmo, Nina.

Afiliação

Norum J; Department of Surgery, Finnmark Hospital, Hammerfest, Norway.
Antonsen MA; Department of Pharmacy, Hospital Pharmacy of North Norway Trust, Tromsø, Norway.
Tollåli T; Departments of Medicine, Nordland Hospital, Bodø, Norway.
Al-Shibli K; Department of Pathology, Nordland Hospital, Bodø, Norway.
Andersen G; Division of Diagnostic Services, University Hospital of North Norway, Tromsø, Norway.
Svanqvist KH; Department of Reliable Supply, The Norwegian Medicines Agency, Oslo, Norway.
Helbekkmo N; Department of Pulmonary Medicine, University Hospital of North Norway, Tromsø, Norway.

ESMO Open ; 2(3): e000222, 2017.

Article em En | MEDLINE | ID: mdl-29209527

Palavras-chave

cost; effectiveness; non-small cell lung cancer; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google